Peptide News Digest

FDA Career Scientists Briefing Document Says No Peptide Has Sufficient Evidence for 503A Bulks List, STAT: Eight New PCAC Panelists Carry Peptide Industry Ties, PCAC Oral Testimony Closes Today, Medicare GLP-1 Bridge Launches Tomorrow

FDA scientists flag insufficient evidence on 7 peptides; STAT scoops PCAC panelist conflicts; oral testimony closes today; Medicare Bridge launches July 1.

6 stories · Covering regulatory, industry

Editor's Note

Tuesday delivered the substantive regulatory drumbeat that the past two weeks have been building toward. FDA career scientists released briefing documents ahead of the July 23-24 Pharmacy Compounding Advisory Committee meeting concluding that none of the seven peptides (BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax, Epitalon) has sufficient evidence to support 503A bulks list eligibility. The documents cite immunogenicity risk from adverse event data, heavy-metal contamination, microbial contamination, and mislabeled contents in products tested through compounding-pharmacy channels. Coverage ran across NBC News, NPR, the Washington Post, KPBS, and dozens of regional NPR affiliates, with the framing that FDA staff are directly contradicting HHS Secretary RFK Jr.'s public push to expand peptide access. STAT News' June 29 scoop on the eight new PCAC panelists named by FDA Monday found that at least seven of the new members have ties to peptide-related businesses and clinics, including Tennessee state senator Bobby Harshbarger (a pharmacist whose mother Rep. Diana Harshbarger has urged Kennedy to convene the panel) and Dr. Gabriel Alizaidy ($500 peptide consultations). On the procedural calendar, oral testimony registration for the July hearing closed at end-of-day; Medicare GLP-1 Bridge prior-authorization processing through Humana goes live tomorrow Wednesday July 1 for the $50/month obesity-drug coverage demonstration. STAT Pharmalittle also flagged that US lawmakers are investigating whether several large drugmakers have been involved in Chinese clinical trial sites that helped fuel the country's military capability.

Regulatory

FDA Career Scientists Briefing Documents (Released Monday-Tuesday, June 29-30): None of the Seven Peptides Has Sufficient Evidence for 503A Bulks List Eligibility, Citing Immunogenicity Adverse Events, Heavy-Metal Contamination, Microbial Contamination, and Mislabeled Contents in Compounding-Channel Products

FDA career-staff scientists released their briefing documents for the July 23-24 Pharmacy Compounding Advisory Committee (PCAC) meeting, concluding that none of the seven peptides under review (BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax, Epitalon) has sufficient evidence to support 503A bulks list eligibility. The briefing flagged four recurring concerns: limited or inadequate safety data; characterization and impurity concerns; lack of evidence of historical use in compounding meeting bulks-list criteria; and potential immunogenicity risk based on FDA adverse event data showing immune reactions to peptide preparations. The agency also presented data on product-quality failures observed in compounding-channel preparations, including heavy-metal contamination, microbial contamination, and mislabeled contents (some vials testing well below or above the labeled peptide concentration). The conclusion directly contradicts HHS Secretary RFK Jr.'s public position that the Category 2 removals (effective April 23, 2026) were meant to clear the path for 503A bulks list addition. Coverage ran across NBC News, NPR (syndicated to KPBS, Houston Public Media, WLRN, KGOU, HPPR, STLPR), Washington Post, and STAT News. The briefing is the most substantive regulatory development on the seven peptides since the April Federal Register notice.

#fda #pcac #bpc-157 #kpv #tb-500 #mots-c #emideltide #semax #epitalon #rfk-jr #503a #immunogenicity #peptide-safety
Regulatory

STAT News (June 29): Eight New FDA PCAC Panelists Named Monday Carry Peptide Industry Ties: Tennessee State Senator and Pharmacist Bobby Harshbarger (Son of Rep. Diana Harshbarger Who Urged Kennedy to Convene the Panel), Dr. Gabriel Alizaidy ($500 Peptide Consultations), at Least Seven of Eight with Peptide-Business Connections

STAT News reporter Lizzy Lawrence broke a scoop late Monday June 29, 2026 disclosing that the FDA on Monday published the names of eight new panelists who will serve on the July 23-24 Pharmacy Compounding Advisory Committee reviewing seven peptides for 503A bulks list eligibility. The majority of new members are involved with businesses that promote and prescribe peptides, meaning they will be weighing rules changes that could materially benefit them. Specific named members include Bobby Harshbarger, a pharmacist and Tennessee state senator whose mother Rep. Diana Harshbarger (R-TN) is also a pharmacist and has formally urged Kennedy to convene the panel; and Dr. Gabriel Alizaidy, who charges $500 for 'peptide and hormone' consultations that include advice on 'where to safely get each peptide or compound.' UC Davis cell-biology professor Paul Knoepfler told STAT: 'It's concerning that several members of the newly formulated [committee] appear to sell unproven offerings including stem cells and peptides, sometimes both.' FDA rules permit experts with financial stakes to serve on advisory panels as long as the relationship is disclosed and the agency explains why the expertise outweighs the potential conflict. Parallel coverage ran in CNN, PBS NewsHour, Washington Times, and CP24.

#stat-news #pcac #fda #rfk-jr #bobby-harshbarger #diana-harshbarger #gabriel-alizaidy #paul-knoepfler #conflicts-of-interest #peptide-industry
Regulatory

Washington Post (June 30): 'Peptides Are Popular and Controversial. Why?' Mainstream-Media Synthesis Explainer Walks Consumers Through the FDA Staff vs RFK Jr. Tension Two Days Before the Medicare GLP-1 Bridge Launch and Four Weeks Before the PCAC Vote

The Washington Post published a synthesis-explainer piece on June 30, 2026 titled 'Peptides are popular and controversial. Why?' walking consumers through the regulatory tension that has built up over the past month between HHS Secretary RFK Jr.'s public push to expand peptide access and FDA career-scientist briefing documents concluding the evidence is insufficient. The piece sits alongside the Post's parallel reporting (also June 30) titled 'RFK Jr.'s plan to boost peptide access just got more complicated' which framed the FDA staff recommendation as a substantive challenge to the Secretary's agenda. The two Post pieces target different audiences: the first is a consumer explainer (what peptides are, why wellness influencers tout them, what BPC-157 / TB-500 / MOTS-c actually do); the second is a politics-of-policy piece for the regulatory-and-policy audience. Both pieces frame the July 23-24 PCAC meeting as the substantive decision point, while the broader peptide-cultural-moment that the wellness market and STAT, NBC, and NPR coverage have all flagged forms the backdrop. The Washington Times, CNN, and PBS NewsHour ran adjacent coverage.

#washington-post #consumer-education #peptide-culture #rfk-jr #fda #mainstream-media #pcac #wellness-trend
Regulatory

PCAC Oral Testimony Registration Closes Tuesday June 30 at End-of-Day for July 23-24 Pharmacy Compounding Advisory Committee Hearing on BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax, and Epitalon; Written Docket FDA-2025-N-6895 Remains Open Through July 9 for PCAC-Member Review, July 22 for Hard Comment Deadline

Registration for oral testimony at the FDA Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026 closed at the end of business Tuesday June 30, 2026. Individuals or organizations who wanted to give a formal oral presentation at the public-comment portion of the meeting had to notify FDA by today with a brief description of the evidence or arguments to be presented, names and addresses of participants, in-person versus virtual preference, and a requested time allotment. Written comments to docket FDA-2025-N-6895 at regulations.gov remain open through July 9, 2026 for formal provision to PCAC members ahead of the meeting; the hard deadline for all written comments is July 22, 2026 at 11:59 PM ET. The two-day meeting at FDA's White Oak campus in Silver Spring, Maryland (with virtual attendance option) reviews seven peptides for 503A bulks list eligibility: BPC-157, KPV, TB-500, and MOTS-c on Day 1 (July 23); Emideltide (delta sleep-inducing peptide / DSIP), Semax, and Epitalon on Day 2 (July 24). Oral-testimony filers will face the FDA career-staff briefing documents released this week concluding the evidence is insufficient on all seven substances.

#pcac #fda #503a #bulks-list #oral-testimony #deadline #bpc-157 #kpv #tb-500 #mots-c #emideltide #semax #epitalon
Industry

Medicare GLP-1 Bridge Demonstration Goes Live Tomorrow Wednesday July 1: Humana Central Processor Opens for Prior-Authorization Submissions, BIN 028918 / PCN MEDDGLP1BR Pharmacy Billing Active, Walgreens Publishes Pharmacist-Navigation Guidance for Medicare Patients Filling First Foundayo, Wegovy Injection, Wegovy Tablets, or Zepbound KwikPen Prescriptions at $50/Month

The Medicare GLP-1 Bridge demonstration program launches Wednesday July 1, 2026 (one day from this digest), providing eligible Medicare Part D beneficiaries with $50/month access to Foundayo (orforglipron), Wegovy (injection and 1.5/4/9/25 mg tablets), and Zepbound KwikPen through December 31, 2027. Operationally, Humana opens its central-processor function for prior-authorization submissions and claims adjudication starting tomorrow; the Bridge-specific pharmacy billing identifiers (BIN 028918, PCN MEDDGLP1BR) become active for first fills. Walgreens published pharmacist-navigation guidance Tuesday flagging that store pharmacists will help Medicare patients verify eligibility (the three-tier BMI-and-comorbidity criteria walked through in this site's June 29 patient-guide insight), confirm Part D enrollment status, and submit the Bridge prior-authorization request to Humana through the dedicated workflow. CNN published a June 29 consumer explainer flagging that the program is the first time Medicare has paid for drugs prescribed solely for obesity. The Bridge runs in parallel with the broader BALANCE Model launching January 2027 in Part D, with the Bridge ending December 31, 2027 and beneficiaries transitioning to BALANCE.

#medicare-glp-1-bridge #cms #humana #walgreens #july-1-launch #foundayo #wegovy #zepbound #prior-authorization #obesity-coverage
Regulatory

STAT Pharmalittle (June 30): US Lawmakers Investigating Whether Several Large Drugmakers Have Been Involved in Chinese Clinical Trial Sites That Helped Fuel Country's Military Capability: Parallel Track to the BIOSECURE Act and the Insilico-SK Biopharm $2.5B AI Neuroimmune Deal Anchoring BIO 2026 Last Week

STAT News' Pharmalittle column on Tuesday June 30, 2026 disclosed that US lawmakers are investigating whether several large pharmaceutical companies have been involved in clinical trials at Chinese sites that helped advance China's military capability. The investigation runs parallel to the BIOSECURE Act (passed 2024) restricting US biotech contracting with named Chinese CDMOs and gene-sequencing companies, and to the structural anxiety about Chinese scientific output that biotech executives flagged at BIO 2026 last week. The Insilico Medicine (Hong Kong-headquartered) + SK Biopharmaceuticals $2.5 billion AI-neuroimmune drug discovery pact announced June 22 at BIO 2026 opening sits inside this conversation, as do Chinese-API supply chains feeding US gray-market peptide vendors and the licensed-generic semaglutide flow from Indian and Chinese manufacturers post-March 2026 patent expiration. The lawmaker probe expands the regulatory aperture beyond the BIOSECURE Act's named-entity list toward broader scrutiny of US-China clinical-research cooperation. No specific drugmakers were publicly named in the Pharmalittle report.

#china #biosecure-act #clinical-trials #stat-news #lawmaker-probe #insilico-medicine #us-china #pharmalittle